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Abstract
The concept of a pre-emptive strike as a good means to prevent greater harm may be frequently
over-stressed in daily life. However, biological systems in a homeostatic balance are prepared to
withstand a certain degree of hostile fire by rather passive means. This also applies to the
maintenance of cell survival, where a plethora of protective proteins provide safeguard against
erroneous activation of death pathways. Apart from these mechanisms active processes are also
essential for the maintenance of cellular homeostasis, commonly referred to as survival signaling.
Frequently their targets may be mitochondrial, assuring organelle integrity, which is essential for
continued energy production and survival. Transient or permanent failures in these cellular defense
strategies result in pathophysiological conditions, which manifest themselves e.g. as cancer or
ischemia/reperfusion-associated organ damage.
Review
During times of peace cells are dependent on a balanced
crosstalk with their surrounding environment. Survival
and proper functioning not only require physical contact
with their neighbors, but also depend on a plethora of sol-
uble factors such as hormones or growth factors. The full
spectrum of possible cell fates is governed by these mutual
and highly dynamic interactions. In the extreme case a dis-
sonance in this "orchestra of life" leads to cell death. How-
ever, in order for this to happen a variety of safeguard
mechanisms have to fail and cells are normally suffi-
ciently guarded against these threats.
Subversion of intracellular control mechanisms is linked
to many pathophysiological conditions. In particular,
cancer cells are geared towards cellular autonomy, which
is achieved through aberrant activation of intracellular
signaling processes. As a consequence these cells are in a
preemptive way programmed to withstand hostile condi-
tions and to thrive in a growth and survival limiting envi-
ronment. Thus cancer provided a useful model for the
delineation of mechanisms used to counter potential
assaults. Its analysis taught us that tumors in a unique way
are equipped to withstand limitation in life supporting
oxygen or nutrient supply. Many of the genetic defects
found in tumors reside in signaling cascades or proteins,
supporting the key role of aberrant signaling in this. How-
ever, protective mechanisms also can be triggered in a
more rapid and transient fashion. During transplantation
organs are temporarily deprived of oxygen, nutrients and
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growth factors (ischemia). A decrease in myocardial oxy-
gen delivery initially results in decreased contractile activ-
ity and oxygen consumption, a phenomenon termed
hibernating myocardium [1]. Prolonged hypoxia may also
reduce ATP demand by down-regulating protein synthesis
[2]. Restoration of blood flow (reperfusion) corrects these
deficits but at the same time initiates a detrimental cas-
cade, which in the end can lead to irreversible damage of
the affected organ. During reperfusion organs also
respond with the activation of intracellular signaling path-
ways. Some of these signaling activities are clearly linked
to the cell death induction, while others may be involved
in the elicitation of a protective response. Through
repeated short ischemic intervals which do not cause irre-
versible damage ("pre-conditioning"), cells may actually
learn to cope with conditions, which are normally life-
threatening. Also this defense mechanism is operated by
intracellular signaling pathways [3]. Therefore, under-
standing the role of signaling in ischemia-reperfusion
induced injury (IRI) holds the potential for the develop-
ment of novel therapeutic strategies for its prevention,
perhaps even at a time point before other events like the
production of reactive oxygen species (ROS), the pertur-
bation of Ca2+ homeostasis or inflammatory responses
occur, which will greatly amplify the damage. Mitochon-
dria feature prominently in these processes as they are crit-
ical for the provision of energy and the assurance of cell
survival. A coordinated cellular response will require
crosstalk between mitochondria and their cellular envi-
ronment. Cytoplasmic signaling pathways are increas-
ingly recognized for their central role in relaying
information to the mitochondria and in possibly control-
ling their function [4]. In this review we will present a cur-
rent view of mitochondrial form and function, before we
discuss the dealings of mitochondria with the cellular
environment. Finally we will use the example of ischemia/
reperfusion-induced tissue damage to illustrate the coop-
eration of these players and to show up possible therapeu-
tic implications.
From form to function: Mitochondria shaping up 
for performance
The classical view of mitochondria as bean-shaped
organelles has changed dramatically over the last years.
Earlier studies shed light on the complexity of their inter-
nal organization [5], while most recently another feature
of these organelles has attracted considerable interest,
their highly dynamic behavior [6]. Through fission and
fusion mitochondrial morphology can change from small
spheres or short rods to long tubules forming large net-
work-like structures within the same cell. Another level of
complexity is added through their high motility. While
the highest velocity was found in neurons, mitochondrial
movement could be shown in various other cell systems
such as HL-1 cells, cultured fibroblasts, budding yeast, etc.
[7-11]. Mitochondria can be actively transported in cells
and may have defined tissue-specific subcellular distribu-
tions. In neurons, for example, they are translocated to
regions with high energy and Ca2+ buffering demands,
such as active growth cones, pre- and post-synaptic sites.
In addition, they often pause at sites where no mitochon-
dria are present, resulting in an uniform axonal mitochon-
drial distribution. Mitochondria with high membrane
potential preferentially migrate in the anterograde direc-
tion, whereas mitochondria with low membrane poten-
tial move in the retrograde direction. Therefore active
mitochondria appear at distal regions with high energy
demands, while impaired mitochondria are returned to
the cell soma, possibly for repair or mitophagy. In addi-
tion, signaling molecules such as nerve growth factor
(NGF) influence mitochondrial recruitment and retention
[12].
Several studies have suggested that controlling mitochon-
drial shape through fusion and fission is also crucial for
maintaining the functional properties of mitochondria
[6]. The precise balance between these two opposing proc-
esses therefore might play a key role in mitochondrial and
cellular function. More than ten years ago, the first molec-
ular mediator of mitochondrial fusion was discovered in
Drosophila melanogaster: Fusion factor fuzzy onions (Fzo), a
mitochondrial outer membrane GTPase that is required
for the fusion of mitochondria during spermatogenesis
[13]. The two human Fzo homologues Mitofusin (Mfn) 1
and 2 also control mitochondrial morphology [14,15]. As
a subset of mitochondria in Mfn1-deficient cells was
shown to lose their membrane potential, mitochondrial
fusion seems to allow cooperation between mitochon-
dria, thereby protecting mitochondria from respiratory
dysfunction [15]. Also Mfn2 ablation experiments have
documented a reduced mitochondrial oxidation and
membrane potential as well as a repression of nuclear-
encoded subunits of OXPHOS complexes [16]. In mam-
mals, mitochondrial fission requires the recruitment of
cytosolic dynamin-related protein (DRP1) [17]. Post-
translational modifications regulate its function in mito-
chondrial fission. The ubiquitin ligase of the mitochon-
drial outer membrane, termed membrane-associated
RING-CH (MARCH)-V, a member of the transmembrane
RING-finger protein family, has the ability to bind to
Mfn2 and DRP1, to ubiquitinate DRP1 and to modify
mitochondrial morphology. By regulating Mfn2 and Drp1
activities, MARCH-V controls mitochondrial morphology
[18].
In addition, cellular stress influences mitochondrial
fusion and fission: Thus DRP1 was also shown to be
involved in apoptosis-associated mitochondrial fission.
While under normal conditions DRP1 recycles between
the cytoplasm and mitochondria, it shows a stable mem-Cell Communication and Signaling 2008, 6:4 http://www.biosignaling.com/content/6/1/4
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brane association following the recruitment of BAX to the
mitochondrial membrane but before the loss of mito-
chondrial membrane potential. During apoptosis, the
biochemical properties of DRP1 are regulated via a BAX/
BAK-dependent stimulation of small ubiquitin-like mod-
ifier-1 conjugation to DRP1 [19]. Recent findings have
demonstrated a key role of the proper regulation of mito-
chondrial dynamics for various cellular pathways, dem-
onstrating also that defective mitochondrial behavior may
affect human health. For example, several neurological
diseases (e.g. Charcot-Marie-Tooth, CMT; autosomal
dominant optic atrophy, DOA) are associated with muta-
tions in proteins that control mitochondrial dynamics
and morphology like mitofusin-2 and OPA1 [20,21].
Breathing oxygen-producing ROS
The change in earth's atmosphere from anoxic to our cur-
rent conditions of approx. 21% oxygen had on the one
hand catastrophic effects on unicellular anaerobic life
forms but on the other hand paved the way for new forms
of life which managed to tame this highly reactive and due
to its oxidizing properties potentially life-threatening
molecule and made a renegade of it changing fronts from
life threatening to life supporting [22]. The supply of ATP
through oxidative phosphorylation, which couples the
oxidation of metabolic substrates to the synthesis of ATP
from ADP and inorganic phosphate takes place in the
mitochondria, putative descendents of an ancient endo-
symbiotic event between an alpha-proteobacterium and
an archean host [23,24]. Utilizing oxygen as the final elec-
tron acceptor in the aerobic metabolism of glucose as the
primary source of energy increased the efficiency of ATP
generation.
The mitochondrial respiratory chain transfers electrons to
molecular oxygen, permanently producing ROS as a by-
product of oxidative phosphorylation. Depending on the
conditions, a few percents of the oxygen consumed by
mitochondria are reduced by a single free electron with
formation of superoxide radical, which then can be con-
verted to hydrogen peroxide (further mono-electron
reduction of oxygen) by mitochondrial superoxide dis-
mutase (SOD), which in turn can be scavenged by catalase
reaction or converted to the very reactive hydroxyl radical
in the presence of transition metals (e.g. Fe2+). Several
reports have demonstrated that mitochondrial superoxide
production is mostly a result of incomplete reduction of
oxygen at sites of respiratory complexes I (NADH:ubiqui-
none oxidoreductase) and III (CoQ:cytochrome c  oxi-
doreductase) which therefore can be considered as main
sources for mitochondrial ROS [25-29].
Sensing cellular energy status
Mitochondria are able to monitor their surrounding envi-
ronment, including intracellular energy (ATP) levels, as
well as oxygen, ROS, Ca2+ and the presence or absence of
growth factors [4]. Moreover, mitochondria are well tai-
lored to meet both the signaling and metabolic needs of
the cell. It has been suggested that mitochondrial biogen-
esis (mitochondrial proliferation) and dynamics are
strongly linked to the ability of mitochondria to sense
energy status [7,30-33]. In muscles confronted with
increased work load (training, endurance exercise) or
pathological changes (mitochondrial diseases, genetic
defects in respiratory complexes), the proliferation of
mitochondria serves as an adaptational response to
decreased energy levels [33]. In other cells like neurons,
energy sensing mechanisms may also serve for the directo-
rial transport of mitochondria to the cellular regions of
higher energy demands [7]. One of the key enzymes for
low-energy sensing is AMP activated protein kinase
(AMPK) [34]. AMPK is an evolutionarily conserved
enzyme which is allosterically activated by AMP (marker
of low energy status). In addition, AMPK is strongly regu-
lated by changes in phosphorylation state by upstream
kinases and phosphatases [34-36]. This enzyme therefore
is sensitive to increases in the cellular AMP/ATP ratio and
can be activated by various metabolic stresses, such as
ischemia, hypoxia, starvation (e.g. glucose deprivation),
by metabolic inhibition (e.g. using analogs of energy sub-
strates or simulated ischemia) or in response to increased
exercise in muscles [31,37-40]. Stimuli for AMPK involve
either processes that inhibit ATP production or accelerate
ATP consumption. Active AMPK upregulates catabolic
and suppresses anabolic pathways [38,41]. For example,
AMPK may phosphorylate and thus inhibit enzymes of
ATP consuming pathways like the formation of fatty acids,
cholesterol and glycogen (e.g. acetyl-CoA-carboxylase,
glycogen synthase, etc.), and also highly ATP consuming
protein synthesis by eEF2K phosphorylation [42]. Moreo-
ver, active AMPK blocks cell growth and proliferation by
suppression of the target of rapamycin (mTOR) pathway
[43,44] via direct phosphorylation of an upstream regula-
tor of mTOR, tuberous sclerosis complex-2 (TSC2 or
tuberin) [45]. This type of downregulation of mTOR sign-
aling seems to be dominant over the positive effects of
growth factors or amino acids. More recent data suggest
two inhibitory effects of AMPK on mTOR. Activated
AMPK may phosphorylate TSC2 at a site different from
AKT, promoting its Rheb-GAP activity, and additionally it
may phosphorylate raptor (regulatory associated protein
of mTOR), also resulting in mTOR inhibition [46], lead-
ing to a suppression of protein synthesis and overall cellu-
lar ATP consumption. At the same time, AMPK activation
in muscles could markedly stimulate glucose uptake by
increased translocation of the glucose transporter GLUT4
to the plasma membrane [47] via phosphorylation of a
downstream target of AMPK – AS160, a Rab GTPase-acti-
vating protein [48]. Besides, acute or chronic chemical
activation of AMPK in muscles results also in elevatedCell Communication and Signaling 2008, 6:4 http://www.biosignaling.com/content/6/1/4
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GLUT4 expression (with remarkable increase in GLUT4
mRNA levels) [49,50]. Therefore, through activation of
both GLUT4 translocation and GLUT4 expression, acti-
vated AMPK stimulates glycolysis in muscles. In addition,
activation of 6-phosphofructo-2 kinase (PFK) by AMPK
also supports glycolytic ATP production. Furthermore,
phosphorylation of acetyl-CoA carboxylase (ACC) by
AMPK decreases malonyl-CoA levels [51], reducing inhi-
bition of carnitine palmitoyl-CoA acyltransferase-1 (the
enzyme responsible for transport of fatty acids into mito-
chondria), stimulating utilization of fatty acids and help-
ing thus better mitochondrial ATP production. AMPK
activation therefore serves to defend against energy defi-
ciency via activation of glucose transport and oxidation of
fatty acids [34,52-54]. Growing evidence [30,31] demon-
strates that AMPK is also a critical regulator involved in
initiating mitochondrial biogenesis through activation of
the peroxisome proliferator activated receptor γ coactiva-
tor 1α (PGC-1α) which is an important regulator of tran-
scription of many genes involved in mitochondrial energy
metabolism, mitochondrial physiology and oxidation of
glucose and fatty acids [55]. Notably, AMPK also inter-
feres with mitochondrially produced ROS and reactive
nitrogen species (RNS), as well as with their scavengers:
like vitamin E, N-acetylcysteine, the SOD-mimetic MnT-
BAP, or α-Lipoic acid (powerful antioxidant and an essen-
tial cofactor for several mitochondrial enzymes)
[40,56,57].
Metabolic dysregulation is commonly observed under
conditions of metabolic stress, e.g. cancer, ischemia/reper-
fusion. In tumors it may be an important contributor to
the transformation process. Thus the frequently described
switch to glycolysis which also persists under aerobic con-
ditions ("Warburg effect") may in part be caused by direct
effects of cancer protein signaling on the expression/activ-
ity of glycolytic enzymes [58-60]. The discovery of muta-
tions in succinate dehydrogenase and fumarate hydratase,
components of the tricarboxylic acid (TCA) cycle (also
known as Krebs cycle), which connects cytosolic glucose
metabolism to mitochondrial oxidative phosphorylation
(OXPHOS), led to the demonstration of a tumor suppres-
sor function for these proteins [61]. When these genes are
mutated, succinate or fumarate, respectively, accumulate
in mitochondria and pass to the cytosol resulting in the
inhibition of prolyl hydroxylases (PHDs) and consecutive
stabilization of transcription factor hypoxia-inducible fac-
tor 1α (HIF1α) under normoxic conditions [62] with
important consequences for the expression of target genes
required for tumor growth and metastasis. Finally, also
mitochondrial DNA (mtDNA) may carry mutations
which through impairment of OXPHOS, increased ROS
production and increased proliferation contribute to
tumor progression [63].
Controlling mitochondrial function by 
modulating intracellular signaling
Ischemia and reperfusion cannot be avoided during organ
transplantation and initiate a cascade of events, which
results in tissue damage. While advances in immunosup-
pressive therapy, amelioration of surgical techniques and
organ preservation have significantly improved success
rates of solid organ transplantation, IRI remains a major
problem requiring substantial follow up treatment [64-
66].
Massive mitochondrial ROS production during reper-
fusion paralleled by the depletion of scavengers like
superoxide dismutase (SOD), vitamins C and E etc. results
in the deterioration of organ function or even organ loss
[67-69]. There is also evidence that crucial events leading
to ROS production already occur during ischemia [70].
Nevertheless, the major hit to the oxygen-deprived cell
happens, paradoxically, during reperfusion. The reper-
fused cells experience an "oxidative burst" with mitochon-
dria-derived superoxide radicals [71,72]. Mitochondria
are especially sensitive to ROS induced damage and as a
consequence disruption of oxidative phosphorylation can
be observed culminating in significant reduction of ATP
levels, excessive entry of Ca2+ into mitochondria and loss
of mitochondrial membrane potential [73,74], resulting
in cytosolic release of apoptosis inducing factors, such as
apoptosis inducing factor (AIF), cytochrome c and Smac/
DIABLO [75,76].
Attempts to limit ischemia/reperfusion-associated cellular
damage have to take into account the important role of
mitochondria in this process. Current strategies try to
limit the extent of ROS damage by applying anti-oxidants.
Much more desirable would be an approach, which
avoids oxidative damage by preventing ROS production
or scavenging oxygen radicals at the site of their produc-
tion. First evidence for the control of mitochondrial
events by cellular signaling pathways was provided by
demonstrating their effect on the expression and function
of anti-apoptotic proteins of the Bcl-2 or IAP family [77].
Additional support came from the suggested localization
of many diverse signaling molecules (kinases, transcrip-
tion factors, etc.) to various sites in the mitochondria
[4,78]. More difficult was the search for targets regulated
by them due to experimental difficulties. Candidate proc-
esses controlled through signaling include protein and
Ca2+ trafficking, oxidative phosphorylation and produc-
tion of reactive oxygen species. A critical event in cell
death initiation is the translocation of the pro-apoptotic
Bcl-2 protein BAX to the mitochondria [79,80]. Cessation
of survival signals, which is a common stimulus for cell
death induction, will result in the shut-down of signaling
cascades, and in particular the kinases, which compose
them. Since phosphorylation may both positively andCell Communication and Signaling 2008, 6:4 http://www.biosignaling.com/content/6/1/4
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negatively regulate protein function, signal interruption
also will cause the generation of new signals. One of them
originates from GSK-3, which upon activation will cause
the phosphorylation-dependent ubiquitination and sub-
sequent degradation of the survival protein Mcl-1, which
normally negatively controls BAX, followed by its mito-
chondrial translocation [81]. In our work we recently
demonstrated that expression of oncogenic or wild type
RAF prevented mitochondrial ROS production, Ca2+ over-
load and apoptosis [82]. Protein kinase A (PKA) has been
implicated in the activation of the NADH-ubiquinone
oxidoreductase activity of complex I resulting in reduced
ROS production [83,84]. Decreased mitochondrial ROS
levels were also observed in the heart of transgenic mice
expressing the p38 MAPK activator MAPK kinase 6
(MKK6) [85]. Also the tumor suppressor p53 can control
ROS levels through its transcriptional target TIGAR [86],
leading to an increase in the levels of glutathione (GSH),
which scavenges ROS. In contrast, increased mitochon-
drial ROS production has been described for SHC [87,88].
Mitochondrial rheostat of cell survival control Figure 1
Mitochondrial rheostat of cell survival control. Key players in the regulation of mitochondrial function are depicted 
under four different states. Intracellular signaling is represented by bold arrows, filled light grey for survival or dark grey for 
pro-apoptotic signaling. Under normal conditions cells tolerate a certain level of stress before strong pro-apoptotic stimuli 
eventually perturb cellular homeostasis. A tumor cell no longer is in a state of equilibrium as ROS levels usually are high, sur-
vival signals are enhanced and extra-mitochondrial energy production may become predominant. During ischemia/hypoxia oxi-
dative phosphorylation is disturbed leading to a decrease in ATP. Additionally, cells suffer from elevated ROS and Ca2+ levels. 
During reperfusion/reoxygenation mitochondrial ROS and Ca2+ levels peak and cell death may follow. Various intracellular sig-
naling pathways are activated during this time and may positively or negatively control mitochondrial function. Eventually, a 
therapy that abolishes pro-apoptotic signals or elicits survival signaling may help to prevent or limit damage occurring under 
these conditions.Cell Communication and Signaling 2008, 6:4 http://www.biosignaling.com/content/6/1/4
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A fraction of p66 (SHC) exists within mitochondria,
where it oxidizes cytochrome c to form hydrogen perox-
ide, which in turn induces mitochondrial permeability
and apoptosis. Taken together these examples demon-
strate that key mitochondrial processes can be subject to
the regulation by signaling pathways, which normally
respond to extrinsic stimuli (Figure 1). Many of the sign-
aling molecules have attracted considerable interest in the
past because of their role in diverse pathological settings
including autoimmune diseases, inflammation or cancer.
Various approaches have been developed to target them
for therapeutic purposes including the development of
small molecular weight inhibitors. This raises the possibil-
ity of planned pre-emptive intervention to also limit the
extent of IRI.
Production of mitochondrial ROS is not only restricted to
IR but indeed may be an important intermediate in intrin-
sic and extrinsic (cell death receptor-dependent) pathways
of cell death induction. Thus growth factor abrogation
[82,83], death induction through activation of the TNF-α
receptor [89,90] or genotoxic stress [91,92] all are linked
to the induction of massive ROS production, which is
essential for cell death.
Conclusion
Mitochondria long have been recognized for their role as
powerhouse of the cell. Interest in mitochondria was
greatly rekindled upon recognition of their central role in
regulation of cell death. Many death stimuli converge on
these organelles to cause release of apoptogenic factors.
This mitochondrial response is also coupled to the inter-
ruption of energy production and a collapse of mitochon-
dria ROS and Ca2+  homeostasis. However, the latter
processes may also be directly targeted by pro- and antia-
poptotic signaling pathways (Figure 1) opening up possi-
ble novel options for therapeutic interference at an early
stage, before through the release of second messenger like
ROS the damage to cells and organs is amplified.
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